Covance and PathoQuest, a developer of pathogen detection systems, have entered an exclusive agreement to provide Next-Generation Sequencing (NGS)-based biosafety assessments.   This biosafety testing approach, combined with Covance’s regulatory expertise, aims to provide a flexible testing solution for clients and to make biologic medicines safer. The new NGS-based platform is designed to detect and identify viral contaminants within biologic compounds (such as monoclonal antibodies or vaccines...